These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

61 related items for PubMed ID: 8314360

  • 1. Is there a relationship between cytarabine pharmacokinetics and keratitis?--A case report.
    Boos J, Bömelburg T, Gerding H, Jürgens H.
    Int J Clin Pharmacol Ther Toxicol; 1993 Dec; 31(12):593-6. PubMed ID: 8314360
    [Abstract] [Full Text] [Related]

  • 2. High-dose idarubicin in combination with Ara-C in patients with relapsed or refractory acute lymphoblastic leukemia: a pharmacokinetic and clinical study.
    Tedeschi A, Montillo M, Strocchi E, Cafro AM, Tresoldi E, Intropido L, Nichelatti M, Marbello L, Baratè C, Camaggi CM, Morra E.
    Cancer Chemother Pharmacol; 2007 May; 59(6):771-9. PubMed ID: 17256136
    [Abstract] [Full Text] [Related]

  • 3. Pharmacological study of modified intermediate-dose cytarabine therapy in patients with acute myeloid leukemia.
    Sutoh H, Yamauchi T, Gotoh N, Sugiyama M, Ueda T.
    Anticancer Res; 2003 May; 23(6D):5037-42. PubMed ID: 14981964
    [Abstract] [Full Text] [Related]

  • 4. [Is the pharmacokinetic profile of cytarabine clinically relevant?].
    Boos J.
    Klin Padiatr; 1992 May; 204(4):198-203. PubMed ID: 1518256
    [Abstract] [Full Text] [Related]

  • 5. Cerebrospinal fluid and plasma pharmacokinetics of high doses of 1-beta-D-arabinofuranosylcytosine in nonhuman primates.
    Lopez JA, Beardsley GP, Krikorian JG, Mortara RW, Agarwal RP.
    Cancer Res; 1983 Nov; 43(11):5190-3. PubMed ID: 6616454
    [Abstract] [Full Text] [Related]

  • 6. Effect of tetrahydrouridine on the clinical pharmacology of 1-beta-D-arabinofuranosylcytosine when both drugs are coinfused over three hours.
    Kreis W, Chan K, Budman DR, Schulman P, Allen S, Weiselberg L, Lichtman S, Henderson V, Freeman J, Deere M.
    Cancer Res; 1988 Mar 01; 48(5):1337-42. PubMed ID: 3342412
    [Abstract] [Full Text] [Related]

  • 7. Pharmacokinetics of N4-behenoyl-1-beta-D-arabinofuranosylcytosine in patients with acute leukemia.
    Ueda T, Nakamura T, Ando S, Kagawa D, Sasada M, Uchino H, Johno I, Akiyama Y.
    Cancer Res; 1983 Jul 01; 43(7):3412-6. PubMed ID: 6850647
    [Abstract] [Full Text] [Related]

  • 8. Modulation of the cellular metabolism of cytarabine and fludarabine by granulocyte-colony-stimulating factor during therapy of acute myelogenous leukemia.
    Gandhi V, Estey E, Du M, Nowak B, Keating MJ, Plunkett W.
    Clin Cancer Res; 1995 Feb 01; 1(2):169-78. PubMed ID: 9815970
    [Abstract] [Full Text] [Related]

  • 9. Handling punctate keratitis resulting from systemic cytarabine.
    Friedland S, Loya N, Shapiro A.
    Ann Ophthalmol; 1993 Aug 01; 25(8):290-1. PubMed ID: 8239322
    [Abstract] [Full Text] [Related]

  • 10. Cranial irradiation and permeability of blood-brain barrier to cytosine arabinoside in children with acute leukemia.
    Riccardi R, Riccardi A, Lasorella A, Servidei T, Mastrangelo S.
    Clin Cancer Res; 1998 Jan 01; 4(1):69-73. PubMed ID: 9516954
    [Abstract] [Full Text] [Related]

  • 11. Influence of fludarabine on pharmacokinetics and pharmacodynamics of cytarabine: implications for a continuous infusion schedule.
    Seymour JF, Huang P, Plunkett W, Gandhi V.
    Clin Cancer Res; 1996 Apr 01; 2(4):653-8. PubMed ID: 9816215
    [Abstract] [Full Text] [Related]

  • 12. Intracellular retention of cytosine arabinoside triphosphate in blast cells from children with acute myelogenous and lymphoblastic leukemia.
    Boos J, Hohenlöchter B, Schulze-Westhoff P, Schiller M, Zimmermann M, Creutzig U, Ritter J, Jurgens H.
    Med Pediatr Oncol; 1996 Jun 01; 26(6):397-404. PubMed ID: 8614376
    [Abstract] [Full Text] [Related]

  • 13. Plasma and cerebrospinal fluid pharmacokinetics of cytosine arabinoside in dogs.
    Scott-Moncrieff JC, Chan TC, Samuels ML, Cook JR, Coppoc GL, DeNicola DB, Richardson RC.
    Cancer Chemother Pharmacol; 1991 Jun 01; 29(1):13-8. PubMed ID: 1742843
    [Abstract] [Full Text] [Related]

  • 14. High-dose ara-C with autologous peripheral blood progenitor cell support induces a marked progenitor cell mobilization: an indication for patients at risk for low mobilization.
    Tarella C, Di Nicola M, Caracciolo D, Zallio F, Cuttica A, Omedè P, Bondesan P, Magni M, Matteucci P, Gallamini A, Pileri A, Gianni AM.
    Bone Marrow Transplant; 2002 Dec 01; 30(11):725-32. PubMed ID: 12439694
    [Abstract] [Full Text] [Related]

  • 15. Accumulation of arabinosyluracil 5'-triphosphate during arabinosylcytosine therapy in circulating blasts of patients with acute myelogenous leukemia.
    Gandhi V, Xu YZ, Estey E.
    Clin Cancer Res; 1998 Jul 01; 4(7):1719-26. PubMed ID: 9676847
    [Abstract] [Full Text] [Related]

  • 16. Evaluation of cell-killing effects of 1-beta-D-arabinofuranosylcytosine and daunorubicin by a new computer-controlled in vitro pharmacokinetic simulation system.
    Kishi S, Goto N, Nakamura T, Ueda T.
    Cancer Res; 1999 Jun 01; 59(11):2629-34. PubMed ID: 10363985
    [Abstract] [Full Text] [Related]

  • 17. Triapine and cytarabine is an active combination in patients with acute leukemia or myelodysplastic syndrome.
    Yee KW, Cortes J, Ferrajoli A, Garcia-Manero G, Verstovsek S, Wierda W, Thomas D, Faderl S, King I, O'brien SM, Jeha S, Andreeff M, Cahill A, Sznol M, Giles FJ.
    Leuk Res; 2006 Jul 01; 30(7):813-22. PubMed ID: 16478631
    [Abstract] [Full Text] [Related]

  • 18. [High dose ara-C therapy induced bradycardia in an acute myeloid leukemia patient with inv (16)(p13q22)].
    Kumagawa M, Suzuki K, Nagano M, Takamatsu Y, Suzumiya J, Tamura K.
    Rinsho Ketsueki; 2003 Jun 01; 44(6):404-6. PubMed ID: 12884821
    [Abstract] [Full Text] [Related]

  • 19. Enhanced cellular uptake of Ara-C via a peptidomimetic prodrug, L-valyl-ara-C in Caco-2 cells.
    Cheon EP, Hong JH, Han HK.
    J Pharm Pharmacol; 2006 Jul 01; 58(7):927-32. PubMed ID: 16805952
    [Abstract] [Full Text] [Related]

  • 20. Cystathionine-beta-synthase cDNA transfection alters the sensitivity and metabolism of 1-beta-D-arabinofuranosylcytosine in CCRF-CEM leukemia cells in vitro and in vivo: a model of leukemia in Down syndrome.
    Taub JW, Huang X, Ge Y, Dutcher JA, Stout ML, Mohammad RM, Ravindranath Y, Matherly LH.
    Cancer Res; 2000 Nov 15; 60(22):6421-6. PubMed ID: 11103808
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 4.